BiotechTube

Bumetanide + Furosemide

Phase 3Recruiting
0 watching 0 views this week๐Ÿ“ˆ Rising
77
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Cirrhosis

Conditions

Cirrhosis

Trial Timeline

Mar 1, 2026 โ†’ Mar 31, 2029

NCT ID
NCT06941415

About Bumetanide + Furosemide

Bumetanide + Furosemide is a phase 3 stage product being developed by Johnson & Johnson for Cirrhosis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06941415. Target conditions include Cirrhosis.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT06941415Phase 3Recruiting

Competing Products

20 competing products in Cirrhosis

See all competitors
ProductCompanyStageHype Score
SYNB1020SynlogicPhase 1/2
33
peginterferon alfa-2a 180ฮผg + peginterferon alfa-2a 90ฮผg + ribavirinChugai PharmaceuticalPhase 3
77
Fenofibrate IDD-P (Insoluble Drug Delivery-Micro Particle)ShionogiPhase 2
52
Mesenchymal Stem CellRohto PharmaceuticalPre-clinical
23
Mesenchymal stem cellRohto PharmaceuticalPhase 1/2
41
ZibotentanAstraZenecaPhase 1
33
Part A: Placebo (matching zibotentan capsule & matching dapagliflozin tablet) + Part A: zibotentan (dose B) + dapagliflozin + Part B: Placebo (matching zibotentan capsule & matching dapagliflozin tablet) + Part B: placebo (matching zibotentan capsule) + dapagliflozin + Part B: zibotentan (dose A) + dapagliflozin + Part B: zibotentan (dose B) + dapagliflozin + Part B: zibotentan (dose C) + dapagliflozinAstraZenecaPhase 2
52
Placebo (placebo matching zibotentan capsule and placebo matching dapagliflozin tablet) + Zibotentan + placebo (placebo matching dapagliflozin tablet) + Zibotentan + dapagliflozinAstraZenecaPhase 2
52
ARQ 197MerckPhase 1
33
Grazaoprevir/Elbasavir + Grazaoprevir/Elbasavir/RBVMerckApproved
85
Steroids + Basiliximab + Tacrolimus + Enteric-coated Mycophenolic acid (EC-MPA)NovartisApproved
85
Telbivudine + Enecavir + AdefovirNovartisApproved
85
Serelaxin + PlaceboNovartisPhase 2
52
Terlipressin acetate + Serelaxin (RLX030)NovartisPhase 2
52
PasireotideNovartisPhase 1
33
HPN-100 + PlaceboAmgenPhase 2
51
Placebo Comparator + Experimental: Seladelpar 50 mg + Experimental: Seladelpar / MBX-8025 200 mgGilead SciencesPhase 2
51
TDF/FTC/LPV/r + PlaceboGilead SciencesPre-clinical
22
MBX-8025 2 mg Capsule + MBX-8025 5 mg Capsule + MBX-8025 10 mg CapsuleGilead SciencesPhase 2
51
Seladelpar 5 mg Capsule + Seladelpar 10 mg CapsuleGilead SciencesPhase 3
76

Other Products from Johnson & Johnson

Fentanyl transdermal therapeutic systemApproved
85
Nicotine Gum + Nicotine PatchApproved
85
galantamineApproved
85
IbrutinibApproved
85
Paliperidone ERApproved
85